{"entity":{"id":"ptx-912","kind":"drug","name":"PTX-912","aka":[],"tldr":"PTX-912 is an experimental immune-stimulating protein from Proviva Therapeutics, in phase 1 trials for advanced solid tumours.","summary":"PTX-912 is a fusion protein (interleukin-2 prodrug) from Proviva Therapeutics. An interleukin-2 prodrug fusion protein meant to be switched on inside the tumour; Chinese financing reports describe it differently (one as immune-cell-targeted, one as a PD-1/IL-2 fusion), so no target is linked. The phase 1 study NCT06190886 is recruiting people with advanced solid tumours. Whether it works in people has not been established.","status":"phase-1","asOf":"2026-11-04","links":[{"label":"PEdaily report on the Proviva Series A, March 2024","url":"https://news.pedaily.cn/202403/530729.shtml"},{"label":"ClinicalTrials.gov NCT06190886","url":"https://clinicaltrials.gov/study/NCT06190886"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["proviva-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06190886"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors, investor portfolios (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-04"},"code":"PTX-912","modality":"Fusion protein (interleukin-2 prodrug)","mechanism":"An interleukin-2 prodrug fusion protein meant to be switched on inside the tumour; Chinese financing reports describe it differently (one as immune-cell-targeted, one as a PD-1/IL-2 fusion), so no target is linked.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ptx-912/","neighbours":{"company":[{"id":"proviva-therapeutics","kind":"company","name":"Proviva Therapeutics","route":"/companies/proviva-therapeutics/"}],"trial":[{"id":"nct06190886","kind":"trial","name":"A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors","route":"/trials/nct06190886/"}]}}